Skip to main content

Advertisement

Table 3 Percentage of patients with adverse effects observed in the COMPARZ study

From: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

ADVERSE EFFECT PAZOPANIB SUNITINIB
Fatigue
 Any grade 50% 63%
 Grade 3–4 10% 17%
Hand-foot syndrome
 Any grade 29% 50%
 Grade 3–4 6% 11%
Stomatitis
 Any grade 14% 27%
ALTb 60% 43%
Fatal AEas 2% 3%
Fatal treatment-related AEs 3 cases 8 cases
  1. aAE: adverse events; bALT: alanine aminotransferase